Fintel reports that on February 28, 2025, William Blair initiated coverage of Corbus Pharmaceuticals Holdings (LSE:0SZI) with a Outperform recommendation. There are 220 funds or institutions ...
William Blair started coverage on shares of Structure Therapeutics (NASDAQ:GPCR – Free Report) in a research note published on Friday, Marketbeat Ratings reports.
Fintel reports that on February 28, 2025, William Blair initiated coverage of Altimmune (LSE:0A4C) with a Market Perform recommendation. There are 326 funds or institutions reporting positions in ...
Hosted on MSN4mon
Cargo Therapeutics draws bullish view at William Blair on lead assetCell therapy developer CARGO Therapeutics (NASDAQ:CRGX) traded higher on Tuesday after William Blair launched its coverage with an Outperform recommendation, citing the potential in its lead ...
Research analysts at William Blair initiated coverage on shares of Immunic (NASDAQ:IMUX – Get Free Report) in a research note issued to investors on Tuesday, Marketbeat.com reports.
On Monday, William Blair reaffirmed a Market Perform rating on Kenvue Inc (NYSE:KVUE), a consumer health company with a market capitalization of $38.69 billion. According to InvestingPro data, the ...
Investing.com -- William Blair upgraded Palantir Technologies (NASDAQ:PLTR) to Market Perform following a 33% selloff from $125 to $84 over the past three weeks, despite concerns over its valuation.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback